Alebund Unveils Promising Phase 3 AP301 Trial Results at ASN 2025 Congress in Houston #China #Houston #Alebund #AP301 #Hyperphosphatemia
0
0
0
0
Alebund Unveils Promising Phase 3 AP301 Trial Results at ASN 2025 Congress in Houston #China #Houston #Alebund #AP301 #Hyperphosphatemia
Alebund Pharmaceuticals Achieves Success in Phase 3 Study of AP301 for Dialysis Patients #China #Shanghai #Alebund #AP301 #Hyperphosphatemia
Alebund Pharmaceuticals Secures RMB 550 Million to Advance Innovative Kidney Treatments #China #Series_C_Funding #Alebund #renal_therapies #Yangzhou